Risk factor
Very high price volatility
Profitability factor
Undervalued vs peers
About
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.
Company Valuation
From both historical and forecast perspectives, the stock is underpriced compared to similar stocks.
Target Price
The average target price of STX.L is 17.2 and suggests 177% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr